Phase-1 MAD study to evaluate GDC-6988, a dry powder formulation of a selective inhaled potentiator of TMEM16A

A Phase-1 multiple ascending dose healthy volunteer study to evaluate the safety, tolerability, and pharmacokinetics of GDC-6988, a dry powder formulation of a selective inhaled potentiator of TMEM16A

Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are not indicated for ~10% of people with CF and may not fully restore CFTR function. Here we present blinded outcomes from an ongoing Phase 1 study of a dry powder (DP) formulation of GDC-6988.